2018
Thermo Fisher Scientific Declares Quarterly Dividend
November 8, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per common share...
Thermo Fisher Scientific Declares Quarterly Dividend >
Thermo Fisher Scientific Showcases Innovations for Research and Clinical Labs at AACC 2018
July 31, 2018
AACC -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its latest innovations for clinical and translational research during the 2018 American...
Thermo Fisher Scientific Showcases Innovations for Research and Clinical Labs at AACC 2018 >
Thermo Fisher Scientific Reports Second Quarter 2018 Results
July 25, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 30, 2018. Second Quarter 2018 Highlights Grew...
Thermo Fisher Scientific Reports Second Quarter 2018 Results >
New Thermo Scientific B·R·A·H·M·S PCT direct blood test allows fast bacterial infection and sepsis diagnosis at patient’s point of care
July 17, 2018
The new B·R·A·H·M·S PCT direct point of care assay requires just one drop of blood for a reliable infection diagnosis and clinical decisions in the acute care setting within 20 minutes.
New Thermo Scientific B·R·A·H·M·S PCT direct blood test allows fast bacterial infection and sepsis diagnosis at patient’s point of care >
Thermo Fisher Scientific Declares Quarterly Dividend
July 13, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per common share...
Thermo Fisher Scientific Declares Quarterly Dividend >
Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis
July 13, 2018
Elecsys® B·R·A·H·M·S PCT™ (procalcitonin) helps clinicians assess presence and severity of certain bacterial infections and patient response to antibiotics
Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis >
10th International Workshop on Prenatal Screening
June, 2018
The 10th International Workshop on Prenatal Screening, organized by Thermo Fisher Scientific, took place in Berlin. Almost 170 participants from 28 countries attended the workshop. As already in the previous years the highly scientific program with internationally well recognized speakers makes it a much appreciated event on prenatal screening. For further information about lectures and speakers please get in contact with us.
Contact us >
Read more on prenatal screening >
New Thermo Scientific B·R·A·H·M·S KRYPTOR GOLD Analyzer Instrument Combines Higher Throughput and Maximum Autonomy
June 15, 2018
New KRYPTOR GOLD instrument features the precision and productivity required for clinical specialty diagnostics laboratories and patient diagnosis and prognosis research
Read the News Press Release here >
Find more about B·R·A·H·M·S KRYPTOR GOLD >
Thermo Fisher Scientific supports the European STATIN trial to evaluate pravastatin in the potential prevention of preeclampsia
June 5, 2018
Research results suggest a preventive role of statins in the late-onset form of preeclampsia
Read the News Press Release here >
Thermo Fisher Scientific Supports World Preeclampsia Day on May 22
May, 2018
May 2018 is the pre-eclampsia awareness month with World Preeclampsia Day happening on May 22. Pre-eclampsia is a rare and severe pregnancy complication affecting about 2-8% of pregnancies worldwide. Thermo Fisher Scientific is proud to support this important initiative to create awareness about the symptoms and risks of this disease, but also to inform about the benefits of an early screening test which can be an advise for possible preventive measures and possible prevention in order to improve pregnancy outcome.
EFCNI (European Foundation for the Care of Newborn Infants) >
Thermo Fisher Scientific Reports First Quarter 2018 Results
April 25, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 31, 2018.
Thermo Fisher Scientific Reports First Quarter 2018 Results >
New Publication: The use of MR-proADM in assessing disease severity and treatment response in patients with sepsis and septic shock
March 26, 2018
In collaboration with the SepNet Critical Care Trials Group, a new analysis of 1089 patients with sepsis and septic shock across 33 German Intensive Care Units was recently published in Critical Care. MR-proADM could add significant value to identifying patients at risk of further disease progression, the earlier escalation of therapy in patients at risk of treatment failure, and the subsequent de-escalation of treatment and early discharge of low risk patients.
Read the News Press Release here >
Read the full publication here >
Thermo Fisher Scientific Increases Quarterly Dividend
January 31, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.17 per common share, payable on April 16, 2018, to shareholders of record as of March 15, 2018. This reflects a 13% increase over the previous dividend payment of $0.15.
Thermo Fisher Scientific Increases Quarterly Dividend >
Procalcitonin / Health Economics
Copeptin / Research
